An­oth­er Hu­mi­ra copy­cat comes through in PhI­II; Tetra Dis­cov­ery adds $10M for Alzheimer’s drug de­vel­op­ment

Add one more Hu­mi­ra biosim­i­lar to your watch list. Mo­men­ta says that its Phase III of its knock­off suc­ceed­ed in es­tab­lish­ing its equiv­a­lence to the orig­i­nal. The tri­al met its pri­ma­ry and all sec­ondary end­points, ac­cord­ing to a SEC fil­ing. The news pro­vid­ed a bump in the com­pa­ny’s share price. Hu­mi­ra has at­tract­ed con­sid­er­able at­ten­tion from ri­vals which would like a slice of the megablock­buster mar­ket it en­joys. Ab­b­Vie, mean­while, plans to spare no ex­pense in de­lay­ing these knock­offs for as long as it can.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER